18 min listen
EP 90: Patient-centric drug development in ALS with Ronald van der Geest, Chief Development Officer of Treeway
EP 90: Patient-centric drug development in ALS with Ronald van der Geest, Chief Development Officer of Treeway
ratings:
Length:
35 minutes
Released:
Dec 8, 2022
Format:
Podcast episode
Description
"If someone tells you it’s not possible, then it’s interesting" according to Treeway Chief Development Officer Ronald van der Geest.
Founded in 2012 by two ALS patients who refuse to take their diagnoses lying down, Treeway develops novel treatments for ALS, Alzheimer's disease, and other neurodegenerative diseases.
Join Patrick and Ronald in our latest podcast episode as they explore Treeway’s roots, the four major disciplines required for successful development of novel treatments, discuss the landscape of ALS treatment options in 2022, and celebrate the power of a small group of people, smart design and resilience.
Founded in 2012 by two ALS patients who refuse to take their diagnoses lying down, Treeway develops novel treatments for ALS, Alzheimer's disease, and other neurodegenerative diseases.
Join Patrick and Ronald in our latest podcast episode as they explore Treeway’s roots, the four major disciplines required for successful development of novel treatments, discuss the landscape of ALS treatment options in 2022, and celebrate the power of a small group of people, smart design and resilience.
Released:
Dec 8, 2022
Format:
Podcast episode
Titles in the series (100)
EP 8 Dr Sonya Abraham on biologics, arthritis and the gut microbiome: Sano Genetics CEO Dr Patrick Short interviews Dr Sonya Abraham, a researcher at Imperial College, London who looks at different conditions like arthritis and psoriasis to discuss biological therapies (or biologics) and how the gut microbiome affects... by The Genetics Podcast